Delaware Judge Axes Novartis Patent On Heart Failure Drug

By Ryan Davis · July 7, 2023, 9:01 PM EDT

A Delaware federal judge ruled Friday that a patent covering Entresto, a blockbuster heart failure drug made by Novartis, is invalid for lacking an adequate written description, handing a win to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

In re: Entresto (Sacubitril/Valsartan) Patent Litigation

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

March 27, 2020

Recent Articles By Ryan

December 16, 2024
The Biggest Patent Decisions Of 2024
November 21, 2024
In Tight Vote, Senate Panel OKs Bill To Set New PTAB Limits
October 28, 2024
Judge Leaves Patent Case After Fed. Circ. Undoes Ruling
October 18, 2024
What Attorneys Expect From Harris And Trump On Patents
October 07, 2024
High Court Rejects Pleas To Hear 7 Patent Cases
September 26, 2024
Senate Patent Bill Markups Delayed Until After Election
September 18, 2024
Fed. Circ. Revives Astellas Patent Axed As Natural Law
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
June 21, 2024
Drugmakers Decline To Drop Patent Listings After FTC Letters
April 04, 2024
Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents